Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Lannon

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Neuropharmacology|June 1, 1989
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's diseaseJ H Friedman, M C Lannon
Clinical Neuropharmacology|August 1, 1992
Exacerbation of parkinsonism by tacrineB R Ott, M C Lannon
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1990
Clozapine-responsive tremor in Parkinson's diseaseJ H Friedman, M C Lannon
Neurology|September 1, 1989
Clozapine in the treatment of psychosis in Parkinson's diseaseJ H Friedman, M C Lannon
Hospital Practice (Office Ed.)|January 15, 1985
Parkinson disease. Individualizing therapyR G Feldman, M C Lannon
Journal of Geriatric Psychiatry and Neurology|January 1, 1995
Quantitative assessment of movement in Alzheimer's diseaseB R Ott, S A Ellias, M C Lannon
Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 1989
Preparation of manual movements in hemiparkinsonismR D Rafal, J H Friedman, M C Lannon
Journal of Clinical Pharmacology|November 1, 1986
Parkinson's disease: follow-up after "drug holiday"R G Feldman, J A Kaye, M C Lannon
Movement Disorders : Official Journal of the Movement Disorder Society|June 1, 2000
Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's diseaseH H Fernandez, M C Lannon, J H Friedman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trialS A Factor, J H Friedman, M C Lannon, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Neuropharmacology|June 1, 1989
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's diseaseJ H Friedman, M C Lannon
Clinical Neuropharmacology|August 1, 1992
Exacerbation of parkinsonism by tacrineB R Ott, M C Lannon
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1990
Clozapine-responsive tremor in Parkinson's diseaseJ H Friedman, M C Lannon
Neurology|September 1, 1989
Clozapine in the treatment of psychosis in Parkinson's diseaseJ H Friedman, M C Lannon
Hospital Practice (Office Ed.)|January 15, 1985
Parkinson disease. Individualizing therapyR G Feldman, M C Lannon
Journal of Geriatric Psychiatry and Neurology|January 1, 1995
Quantitative assessment of movement in Alzheimer's diseaseB R Ott, S A Ellias, M C Lannon
Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 1989
Preparation of manual movements in hemiparkinsonismR D Rafal, J H Friedman, M C Lannon
Journal of Clinical Pharmacology|November 1, 1986
Parkinson's disease: follow-up after "drug holiday"R G Feldman, J A Kaye, M C Lannon
Movement Disorders : Official Journal of the Movement Disorder Society|June 1, 2000
Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's diseaseH H Fernandez, M C Lannon, J H Friedman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trialS A Factor, J H Friedman, M C Lannon, et al.
Pageof 2